Abstract
confirmed with 13C-urea breath test 4-8 weeks after therapy. Compliance/tolerance: Compliance was determined through questioning and recovery of empty medication envelopes. Incidence of adverse effects was evaluated by means of a questionnaire. RESULTS: 700 consecutive patients were included (mean age 48 years, 46% males, 20% peptic ulcer and 80% functional of non-investigated dyspepsia): 344 in group A (standard) and 356 in group B (optimized). Compliance with treatment was 94.5% and 95.9% in groups A and B (nonstatistically significant differences). Per-protocol eradication rates in groups A and B were 87.7% (95%CI=84-91%) and 93.5% (91-96%) (p 90% (both by protocol and by intention-to-treat). This optimized regimen is more effective than the standard one. Although the incidence of adverse effects is higher with the optimized treatment, these are mostly mild, and do not negatively impact the compliance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
